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CHAPTER ONE
LITERATURE REVIEW
Statement of the Problem
Anemia is a condition in which there is a lack of enough healthy red blood cells. Anemia
is a pervasive side effect in multiple myeloma (MM) patients occurring in more than two thirds
of all patients [1]. MM is an incurable hematological malignancy characterized by the numerous
plasma B cell lesions in the bone marrow (BM). In MM patients, anemia is present with low red
blood cell counts that are contributed to circumstances other than a nutrient deficiency [2]. At the
time of being diagnosed, the prevalent clinical symptom in MM patients is normochromicnormocytic anemia in around 75% of patients [2]. It can be surmised then that anemia in MM
stems from a lack of red blood cell (RBCs) production. Erythropoiesis is the process where
hematopoietic stem cells (HSCs) develop into mature erythrocytes (red blood cells) [3]. This
process is hampered in MM [4].
Multiple Myeloma
In the United States, the lifetime risk of getting MM is 1 in 132 [5]. The American
Cancer Society’s estimates in the United States in 2021 that about 34,920 new cases will be
diagnosed with MM (19,320 in men and 15,600 in women) and about 12,410 deaths are expected
to occur (6,840 in men and 5,570 in women) [6]. In a healthy BM, plasma cells are normally
found inside the BM which make proteins called antibodies to fight infections. In a MM BM,
plasma cells become cancerous and turn into MM cells that produce abnormal antibodies known
as M-proteins [7]. When there are too many myeloma cells, they crowd out normal blood cells in
1
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the bone marrow causing damage to bones, kidneys, and other organs [8-11]. The clinical
features of MM are well remembered with the acronym CRAB which stands for calcium
elevation, renal complications (elevated creatine and BUN), anemia (low Hgb and RBCs), and
bone (pain, lesions, factures) [12]. The focus of this paper is on anemia.
The Sympathetic Nervous System
The human body has a host of defense mechanisms to combat itself against detrimental
situations/conditions. One of the most crucial defense mechanisms is the activation of the
Sympathetic Nervous System (SNS). The SNS is part of our Autonomic Nervous System and
thus is activated involuntary to regulate bodily functions [13]. The SNS becomes activated upon
the perceived ensuing event of harm/physiological stress [13]. This has led to people aptly
naming it the body’s “fight or flight response.” SNS in a more detailed sense involves adrenergic
signaling [14]. Adrenergic signaling is the release of neurotransmitters and the subsequent
cascade of cellular events upon binding of them to their receptors [14]. The neurotransmitter
norepinephrine and the hormone epinephrine are known as catecholamines that are involved in
adrenergic signaling [14]. Conservatively, when a life threat/stress is sensed, it first activates the
hypothalamus to send signals to the adrenal gland [15]. The adrenal gland then releases the
hormone epinephrine and the neuro-transmitter norepinephrine [15]. Though this response is
often a beneficial regulatory mechanism to aid our body, there are circumstances where it can do
the opposite and be harmful.
Sympathetic Nervous System in Hematological Cancers
One area that has been gaining traction in the last 5 to 6 years is the correlation between
the SNS and cancer. Investigations into the SNS causing adverse symptoms in hematological
cancers is particularly of note due to its widening notoriety and comprehension amongst
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researchers. SNS activation can be induced as a result of hematological abnormalities, in a
process known as hematological stress syndrome [16]. In this process, the body perceives the
hematological abnormality as a stress and thus responds by activating the SNS to combat the
stress. Recent studies have shown that a diverse range of factors including psychological stress,
aging, diabetes, and hematological malignancies can cause hematological abnormalities, and
consequently result in the occurrence of hematological stress syndrome [17-23]. However,
the influence of the SNS occurs not via an acute stress response, but through a sustained SNS
activity [24]. One of the inadvertent issues in hematological malignancies due to sustained SNS
activity initiates from the BM, where hematopoiesis occurs. Hematopoiesis is a process that
involves the production, differentiation, and development of all types of blood cells. The BM is
innervated by sympathetic nerve fibers [17]. This includes the Bone Marrow Niche (BMN)
which in addition to sympathetic nerve fibers also contains Schwann cells [17,24]. The BMN is
located on the perivascular space of the BM proximal to where Hematopoietic Stem Cells
(HSCs) reside [25]. In the BM, the constant and enduring stream of catecholamines leads
to durable alteration of the gene expression profile of the cancer and supporting stroma elements
[26-29]. The fostering of HSC commitment in BMN is one aspect of the supporting stroma and
as is evident may contribute to a disturbed BM environment. Along these lines, it stated that
there is evidence through a multitude of epidemiologic and experimental bodies of work that a
stress response induced through the SNS plays a significant part via indirectly aiding in the
creation of tumor-favorable microenvironment [30-36].
Sympathetic Nervous System Role in Multiple Myeloma
One of the most lethal types of hematological cancer is MM. Much has gone into
researching the SNS’s role in the development and progression of MM. Recent studies have

3

4

shown that SNS input is one of the factors that modulates myeloma growth and survival [37]. In
addition, pharmacological inhibition of this sympathetic input was revealed to improve survival
outcomes in patients with MM [38]. Both of the above studies describe the impact of SNS on
myeloma cells. However, there are other aspects involving the BM where the activation of the
SNS can lead to complications during MM. A clinical trial conducted on 25 randomized MM
patients found that after successful HSC engraftment following irradiation of the MM BM, that
poor outcomes were persistent [39]. Gene expression analysis of mature blood cells obtained
from peripheral blood extracts, indicated the upregulation of genes from myeloid lineage cells
[39]. Myeloid lineage cells are cells that are derived from granulocyte-macrophage-progenitors
(GMPs) during BM myelopoiesis [40]. Due to previous knowledge that the use of beta-blockers
can lead to better prognosis in MM, Propranolol was administered to MM patients [38].
Propranolol is a non-specific beta-adrenergic receptor (β-AR) antagonist. Upon Propranolol
administration, gene expression analysis revealed that the upregulation of genes from myeloid
lineage cells seen in MM prior to Propranolol administration had been mitigated [39]. This
implies that sufficient disruption of adrenergic signaling can lead to a shift away from the
myeloid lineage cell bias seen in the peripheral blood of MM patients. This is reasonable as the
SNS is known to have a regulatory influence on hematopoiesis [41,42]. As noted earlier,
hematopoiesis occurs in the BM and the matured blood cells enter into the peripheral circulation
exiting the BM. As addressed in the HCT study, blocking adrenergic signaling leads to a
decrease in mature myeloid lineage cells in the peripheral blood of MM patients. Taken together,
one can question if the bias towards myeloid lineage cells in the peripheral blood of MM patients
stems from the effect of adrenergic signaling in the BM niche.

4
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In-vivo Murine Studies Involving Burn Injury (Prior Lab Data)
Previous studies done by our lab investigated the effects on HSPCs due to adrenergic
signaling in burn injury models. Studies on burn patients in the intensive care unit (ICU) found
that 77% of patients were anemic at the time of hospital discharge [43]. Furthermore, anemic
symptoms had persisted as far as 20 weeks post burn in these patients [43]. Burn injury is
perceived by the body as a physiological stress and therefore induces a SNS response. This led
the previous members of our lab to investigate whether the SNS was responsible for the post
burn anemia seen in burn injuries. An in-vivo study was conducted on mice to test the correlation
between adrenergic signaling (SNS response) and anemia in burn injuries [44]. Mice were either
administered a burn or no burn. After administration, the mice were injected once daily for seven
days with saline-control or propranolol-β-AR antagonist. BM samples were collected on post
burn day 3 and 7. Collected aspirates were sorted using magnetic isolation (method outlined in
Experimental Methods) to isolate LIN NEG population to examine HSPCs. HSPCs were then
surface stained to identify GMPs and megakaryocyte-erythrocyte-progenitors (MEPs) and
intracellular incubated with FITC tagged anti-MAFB to determine MAFB expression (method
outlined in Experimental Methods). A separate model was done in conjunction of subcutaneous
injections using a Alzet pump instead to dispense a continuous dose of saline-control or
propranolol-β-AR antagonist for 14 days [44]. Quantifications for both models were done using
FACS and FLOWJO-software for various parameters (method outlined in Experimental
Methods).
MAFB Expression is Increased in Burn Injury due to Adrenergic Signaling
Transcription factors play a critical role in a complex and highly orchestrated process of
directing HSCs towards lineage commitment by regulating lineage-specific gene expression,

5

6

proliferation, and differentiation. Importantly, the regulation of differentiation by transcription
factors is not merely via a “presence or absence of expression” mechanism but by a dosedependent effect. MAFB (v-maf musculoaponeurotic fibrosarcoma oncogene homolog B) is a
key orchestrator of lineage commitment and differentiation of HSPCs [45]. It plays a pivotal role
as it is required for most myeloid-derived cells [45,46]. It was revealed that MAFB was
expressed at higher levels in BM progenitors of burned mice versus sham mice (Figure 1A,B)
[44]. In addition, propranolol administration to burned mice effectively decreased MAFB
expression demonstrating up-regulation of MAFB in burn injury is due to adrenergic signaling
(Figure 1A,B) [44]. It was also discovered amongst hematopoietic stem and progenitor cells
(HSPCs), there was a myeloid bias at the expense of erythroid progenitors in burned mice
resulting in enhanced development of GMPs and reduced development of MEPs. Upon
administration of propranolol, the higher number of GMPs and lower number of MEPs were
reversed in burned mice (Figure 1C,D) [44]. Through these studies it was established that the
high MAFB expression in HSPCs after burn injury skews their lineage bias towards a myeloid
commitment [44]. Furthermore, it was found that this increase in MAFB expression was due to
adrenergic signaling [44].
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Figure 1. In-Vivo Burn Murine Model. GMP Levels Increase, and MEP Levels Decrease
After Burn Injury due to Increased MAFB Expression which is Under β-AR Control.
Burned and not burned mice were injected once daily for seven days with saline-control or
propranolol-β-AR antagonist. BM samples were collected on post burn day 3 and 7. A separate
model was done in conjunction of subcutaneous injections using a Alzet pump instead to
dispense a continuous dose of saline-control or propranolol-β-AR antagonist for 14 days. (A)
Fluorescent Imaging was used to visually outline differences in MAFB expression between
collected BM samples of sham, post burn day 7 without propranolol, and post burn day 7 with
propranolol. MAFB expression was determined through FITC-conjugated primary antibody. A
DAPI nuclear stain was applied to identify healthy HSPCs. HSPCs from sham sample showed
minimal positive MAFB expression. HSPCs from post burn day 7 sample showed increased
positive MAFB expression compared to sham, but expression returned to near sham levels when
propranolol was administered. (B) MAFB expression increased during post burn day 3 and 7, but
effective blockage of β-AR did not take effect till day 7. Continuous 14-day study confirms day
7 analysis of increased MAFB expression in burn versus sham with propranolol effectively
lowering MAFB expression in burn mice. (C) MEPs are reduced in post burn day 3 and 7
compared to sham. Treatment with propranolol shows recovery of MEP population during post
burn day 7. Findings were reaffirmed through 14-day study. (D) GMPs are increased in post burn
day 3 and 7 compared to sham. Treatment with propranolol shows reduction in GMP population
during post burn day 7. Findings were reaffirmed through 14-day study. This figure was
provided by Dr. Muthumalaiappan with consent to use in this thesis [44].
Murine MAFB Silencing Study in Burn Injury
In conjunction to in-vivo studies an ex-vivo silencing study was conducted on the
transcription factor MAFB (Figure 2) [44]. Silencing of MAFB was done in common myeloid
progenitors (CMPs) which are the highest order of HSPCs and thereby differentiate into GMPs
7
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and MEPs. Samples were harvested bilaterally from femurs of day 7 sham and burned mice.
Sorted CMPs were obtained through flow cytometry and placed in culture with myelo-erythroid
growth factor cocktail. Knock down of MAFB was performed a day later through MAFB siRNA
transfection (method outlined in Experimental Methods). After transfection CMPs were extended
in culture for six more days. Incubation with anti-MAFB allowed for measurement of MAFB
expression using fluorescent imaging and FACS. It was identified that high MAFB in CMPs acts
as a transcriptional activator of MCSF-R (monocyte/macrophage colony stimulating factor 1
receptor) and CD11B (integrin alpha M), which are both critical for myeloid lineage
commitment (Figure 2A,B) [44]. Additionally, MAFB was found to repress the erythroid lineage
marker CD71 i.e. transferrin receptor, demonstrating reduced erythroid differentiation (Figure
2C,D) [44].
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Figure 2. Ex-Vivo Burn Murine Model. MAFB Silencing in Burn CMPs Improves
Erythropoiesis at the Expense of Myelopoiesis. CMPs were collected from post burn day 7
mice and day 7 sham mice. Knock down of MAFB in CMPs was done the next day and extended
in culture for 6 more days. Control samples of both sham and burn which did not receive siRNA
transfections were also placed in cultures. On day 7 various parameters were measured such as
MCSF-R, CD11B and CD71. (A) On day 0 before transfection with siRNA of MAFB, CMPs
were incubated with anti-MAFB and fluorescent imaging was done to obtain initial readings of
MAFB expression in CMPs. (B) MCSF-R is increased in burn compared to sham. MAFB
silencing results in lowered MCSF-R expression in both sham and burn CMPs. (C) CD71
expression is increased and CD11B expression is decreased upon knock down of MAFB in
CMPs. (D) Of the CMP population, CD71 expressing myeloid progenitors increase when MAFB
is silenced. This figure was provided by Dr. Muthumalaiappan with consent to use in this thesis
[44].
Late Erythroid and Myeloid Development in Burn Injuries from Murine Model
To observe ongoing effects of adrenergic signaling on erythroid and myeloid maturation
(erythrocyte/reticulocyte/erythroblast, monocyte, neutrophil development) harvested BM
samples and smears from sham, burn, and propranolol treated burned mice were examined
(Figure 3) [44]. Ter119 and CD71 are essential erythroid markers that can be used to identify the
later stages of erythroid development. Harvested BM samples from mice on post burn day 7
(PBD7) were probed with antibodies of TER119 and CD71 and then subsequently read using
FACS. Results conveyed diminished erythrocyte population in burn mice compared to sham that
was recovered upon administration of propranolol (Figure 3A) [44]. Imaging of BM smears
reaffirmed this by showing fewer reticulocytes and more MDSCs in burn mice compared to
sham (Figure 3B) [44]. Treatment with propranolol for 6 days after burn injury then replenished
early erythroblasts and reticulocytes with a significant reduction in MDSCs (Figure 3B) [44].
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Figure 3. Propranolol Recovers the Erythropoietic Development that is Hampered by Burn
Injury and Reduces Granulocytic Cells with Ringed Nucleus, which is Typical of Myeloid
Derived Suppressor Cells (MDSCs). (A) CD71 and Ter119 positive cells represent mature
erythrocytes which are the fewest in burn mice, but increase in number upon propranolol
administration. (B) Representation of eluted BM smear from sham mice, post burn day 7 burn
mice, and burn mice treated with propranolol. Compared to sham, burn shows fewer
reticulocytes and more MDSCs (ringed nucleus). Administering propranolol for six days after
burn injury replenished early erythroblasts and reticulocytes with a significant reduction in
MDSCs. This figure was provided by Dr. Muthumalaiappan with consent to use in this thesis
[44].
MAFB/GATA1 Axis
The in vivo and ex vivo studies transitioned the lab to look at other transcription factors
that may be perturbed due to increased MAFB expression. GATA1 (globin transcription factor 1)
plays an important role in managing hematopoietic lineages. GATA1 is a transcription factor that
promotes erythropoiesis and is essential for HSPCs to differentiate towards erythroid lineage
[47]. MAFB on the other hand acts as a repressor to the protein ETS1 which interacts with and
promotes GATA1 [48-50]. It was determined in CMPs that high expression of MAFB due to
adrenergic signaling caused GATA1 a crucial erythroid developmental factor to decrease in
10
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expression [51]. The higher MAFB and lower GATA1 expression steers CMPs away from the
erythroid lineage and towards the myeloid lineage [51]. Thus, these CMPs will exhibit a myeloid
bias. The expression of MAFB does not completely negate GATA1 expression in CMPs. Instead,
the axis between the two transcription factors leans toward the expression of one more than the
other. Which direction this MAFB/GATA1 axis is leaning determines how the CMPs will
differentiate. If the MAFB/GATA1 axis is more favored towards MAFB expression than those
CMPs will differentiate into GMPs. On the other hand, if the MAFB/GATA1 axis is more
favored towards GATA1 expression than those CMPs will differentiate into MEPs.
In this study we aimed to determine if the insights gained from a HCT study, could be
related to findings that our lab discovered previously in burn injury [39,44,51]. In other words,
does the increase in myeloid lineage cells in the peripheral blood of MM patients originate in the
BM. If so, then is the dysregulation in the balance between transcription factors MAFB and
GATA1 in progenitor cells responsible for this myeloid bias.

1

2

3
Figure 4. Schematic of Hypothesis. [1] What impact does Beta adrenergic stimulation on
HSPCs [2] have towards CMP differentiation due to the MAFB/GATA1 axis [3] and how does
this effect late-stage erythropoiesis.
11
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CHAPTER TWO
EXPERIMENTAL METHODS
BM Aspirates.
MM Samples: In collaboration with Shanmugam Lab, we received mononuclear cells
from bone marrow aspirates of multiple myeloma patients shipped from Emory University,
Atlanta, GA (stored at -80°C in freezer). Specifications about MM patients of each aspirate were
provided by Emory (Table 1).
Table 1. Multiple Myeloma Patient Information. 11 MM patients with associated IDs received
from Emory. Plasma cell morphology percentages detail the amount of myeloma cells present
within samples. Hemoglobin (Hgb) levels for MM samples have a range between 7.9 to 14.2. A
Hgb level below 14 indicates a low Hgb that is indicative of erythropoietic arrest.

BM Controls: Bone marrow (BM) aspirates from four unidentified healthy donors of
age>18 years and <45 years were obtained as an excess portion of the main aspirate not related
to this study from Loyola Health Sciences Transplant Center. Samples were stored at 80ºC in
70% freezing media consisting of 90% fetal bovine serum with 10% dimethyl sulfoxide at
4X106 cells per 1.0 mL in cryotubes until day of experiments. To isolate the mononuclear cells
12
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from total BM aspirates of control subjects, we followed the same Ficoll method used by Emory
for their collection of MM mononuclear cells. Frozen BM aspirates were brought to 37⁰C in a
warm bath and then distilled/washed with PBS solution. BM cells resuspended in PBS were then
carefully layered over Ficoll solution and centrifuged for 35 minutes at 500xg in room
temperature (20-22°C). The buffy coat monolayer containing mononuclear cells were collected
for all experiments.
Plating for Cultures.
Phase 1 culture: An aliquot of thawed BM control and MM samples were washed with
IMDM and counted to determine seeding density and appropriate culture dish. Cells were plated
in 6 well plates for a seeding density of 300,000 to 1,000,000 cells per well or in 12 well plates
when yield was less than 300,000 cells per well. Cells were then placed in Serum Free Expansion
Medium (SFEM) containing; GMCSF (Granulocyte-macrophage colony-stimulating factor),
SCF (Stem cell factor), IL-3 (Interleukin 3 - pluripotent hematopoietic colony-stimulating factor)
and incubated at 37°C with 5% CO2 to foster the survival/proliferation of HSPCs. The
mononuclear cells contain a heterogenous population including monocytes, neutrophils,
lymphocytes, erythroblasts and HSPCs. These mature cells that are still maintained with lineage
cocktail will be sorted out during day 6 (end of Phase 1) extraction.
Phase 2 culture: After completion of Phase I, samples are extended into Phase II cultures
to measure early and late erythroblast development. Phase II cultures last from day 6 to day 16.
Cells collected from Phase I are placed in a growth cocktail consisting of SCF (Stem Cell
Factor), HT (Holo-Transferrin), EPO (Erythropoietin), and SFEM (Serum Free Expansion
Medium). Similarly, to Phase 1 culture cells were counted to determine seeding density when
plating. 100,000 to 300,000 cells were seeded per well in 12 well plates.
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-SFEM: STEM CELL TECHNOLOGIES (Catalog #: 9650)
-SCF: STEM CELL TECHNOLOGIES (Catalog #: 78062.1)
-GMCSF: R&D Systems, Inc. (Catalog #: 7954-GM-020/CF)
-IL-3: STEM CELL TECHNOLOGIES (Catalog #: 78146
-EPO: STEM CELL TECHNOLOGIES (Catalog #: 78007.1)
-HT: Sigma Aldrich (Catalog #: T4132-100MG)
-IMDM (+L-Glutamine, +25mM HEPES, −Phenol Red, +1% Pen/Strap, +10% FBS, +1%
Plasmocin, +1% Amphotericin): Gibco by Life Technologies (Catalog #: 31980097)
Alpha- and Beta-Adrenergic Receptor Stimulation.
Phenylephrine is an alpha-adrenergic receptor agonist and Isoproterenol is a betaadrenergic receptor agonist [56,57]. Each were separately added at 1pM, 1nM, and 1μM to
different wells in Phase 1 and subsequent Phase 2 cultures. Cells were stimulated every other day
throughout cultures.
-Phenylephrine (Phenylephrine hydrochloride): SIGMA Life Science (Catalog #: P6126-10G)
-Isoproterenol (Isoprenaline hydrochloride): SIGMA Life Science (Catalog #: I5627-5G)
Beta Adrenergic Receptor Blockade.
Propranolol, a beta-adrenergic receptor antagonist was added to wells in phase 1 cultures.
After 30 to 45 minutes which is enough time for effective blockage of beta receptors,
Isoproterenol was added to wells.
-Propranolol (Propranolol Hydrocholoride): SIGMA Life Science (Catalog #: P0884-5G)
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Magnetic Isolation.
LIN NEG: Thawed BM cells and Phase 1 cultured cells on day 6 were processed to
identify and study the phenotype of MMPs using a combination of magnetic isolation and flow
cytometry methods. Biotinylated Anti-human CD3, Biotinylated Anti-human CD14, Biotinylated
Anti-human CD19, Biotinylated Anti-human CD20 were incubated with cultured cells along
with Anti-Biotin microbeads. Those cells with microbeads attached are mature cells. Those cells
that do not have the microbeads attached will elute through the column giving us our lineage
negative cells (Lin NEG). We use the Lin NEG cells to isolate HSPCs.
Myeloma cell Isolation: CD138 (Syndecan-1), is a heparin sulphate proteoglycan that
controls tumor cell survival, growth, adhesion and bone cell differentiation in MM [52]. The
CD138 surface marker was used to isolate myeloma cells from MM samples. BM cells are
incubated with biotinylated antibodies of CD138 and subsequently with Anti-Biotin microbeads.
The collected sample that passes through column will have no myeloma cells (CD 138¯).
Myeloma cells retained in column are flushed with 1.0 mL of buffer and then reseeded into
various control BM cells to examine effects of myeloma cells on various parameters.
-MS columns: Miltenyi Biotec (Catalog #: 130-042-201)
-Biotinylated Microbeads: Thermo Fisher Scientific Inc (Catalog #: 11047)
-Anti-Biotin CD3 antibody: Thermo Fisher Scientific Inc (Catalog #: 13-0037-80)
-Anti-Biotin CD14 antibody: Thermo Fisher Scientific Inc (Catalog #: 13-0149-80)
-Anti-Biotin CD19 antibody: Thermo Fisher Scientific Inc (Catalog #: 13-0199-80)
-Anti-Biotin CD20 antibody: Thermo Fisher Scientific Inc (Catalog #: 13-0209-82)
-Anti-Biotin CD138 antibody: Miltenyi Biotec (Catalog #: 130-119-926)
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Staining with Cell Surface Markers for Flow Cytometry.
Lineage negative cells (CD3¯ CD14¯ CD19¯ CD20¯) that flow through the column are
incubated with Anti-CD34, Anti-CD38, Anti-CD45RA, and Anti-CD123 to determine the cell
surface expression of CD34+, CD38+, CD45RA+/-, CD123+/- cells and are purified (flow sort).
Among the Lin neg cells, CD34+ CD38+ HSPC population are selected and re-gated with
CD45RA, and CD123 to distinguish the CD34+ CD38+ CD45RA+/- CD123+ common myeloid
progenitors (CMPs), CD34+ CD38+ CD45RA- CD123- MEPs and CD34+ CD38+ CD45RA+
CD123- GMPs.
Thawed BM cells and Phase 2 cells enriched for erythroblasts, are identified using
differential expression of CD71 and CD235a to distinguish between early erythroblasts
(EEBs/CD71+CD235a¯), late erythroblasts (LEBs/CD71+CD235a+), and non-erythroblasts (NonEryth/ CD71¯CD235a¯).
-V450 conjugated CD45RA antibody: BD Biosciences (Catalog #: 560362)
-APC conjugated CD34 antibody: Thermo Fisher Scientific Inc (Catalog #: CD34-581-05)
-APC conjugated CD38 antibody: Thermo Fisher Scientific Inc (Catalog #: 47-0381-80)
-PeCy7 conjugated CD123 antibody: Thermo Fisher Scientific Inc (Catalog #: 25-1239-42)
-APC conjugated CD235a antibody: Thermo Fisher Scientific Inc (Catalog #: MA5-17697)
-PE conjugated CD71 antibody: Thermo Fisher Scientific Inc (Catalog #: 12-0711-82)
MAFB and GATA1 Intracellular Identification and Quantification by Flow Cytometry.
Purified HSPCs are first fixed and permeabilized using a perm buffer solution and
cytofix/cytoperm solution. After permeabilization and fixation cells are incubated with Anti-
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GATA1 for 48 hours and Anti-MAFB for 24 hours to determine the intracellular expression
patterns of MAFB and GATA1. Cells are washed in a perm wash solution.
-FITC conjugated MAFB antibody: US Biological Life Science (Catalog #: 038061)
-PE conjugated GATA1 antibody: US Biological Life Science (Catalog #: 030259)
-Cytofix/Cytoperm Solution: BD Biosciences (Catalog #: 554714)
-Perm Buffer Solution: BD Biosciences, diluted with DI-water at 10% (Catalog #: 554714)
-Perm Wash Solution: BD Biosciences, diluted with DI-water at 10% (Catalog #: 554714)
Adrenergic Receptor Incubation.
Purified HSPCs are first fixed and permeabilized using a perm buffer solution and
cytofix/cytoperm solution. After permeabilization and fixation cells are incubated with primary
adrenergic receptor antibodies for 24 hours. After 24-hour incubation, cells are washed with a
perm wash solution and then incubated with subsequent FITC conjugated secondary antibodies
for 3 hours.
-Primary unconjugated BETA1 adrenergic antibody: Santa Cruz Biotechnology, Inc. (Catalog #:
sc-47778)
-Primary unconjugated BETA2 adrenergic antibody: Santa Cruz Biotechnology, Inc. (Catalog #:
sc-81577)
-Primary unconjugated BETA3 adrenergic antibody: Santa Cruz Biotechnology, Inc. (Catalog #:
sc-518080)
-Primary unconjugated ALPHA1 adrenergic antibody: Santa Cruz Biotechnology, Inc. (Catalog
#: sc-100291)
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-Primary unconjugated ALPHA2 adrenergic antibody: Santa Cruz Biotechnology, Inc. (Catalog
#: sc-390430)
-Secondary FITC conjugated antibody for ALPHA1/BETA1&2 (Anti-Goat): Santa Cruz
Biotechnology, Inc. (Catalog #: sc-2356)
-Secondary FITC conjugated antibody for ALPHA2/BETA3(Anti-Rabbit): Santa Cruz
Biotechnology, Inc. (Catalog #: sc-2359)
-Cytofix/Cytoperm Solution: BD Biosciences (Catalog #: 554714)
-Perm Buffer Solution: BD Biosciences, diluted with DI-water at 10% (Catalog #: 554714)
-Perm Wash Solution: BD Biosciences, diluted with DI-water at 10% (Catalog #: 554714)
FACS and FLOWJO Analysis.
FACS stands for fluorescent-activated cell sorting and is used to separate our
heterogenous samples of cells into subpopulations. Upon completion of cell surface and
intracellular antibody staining techniques, samples were taken to the FACS core facility for
sample interrogation. Quantitative and qualitative data on fluorophore-labeled cell surface
receptors and intracellular molecules are achieved using multi-channel detectors. Compensation
controls and unstained samples were run to calibrate instrument setting for each experiment. The
FLOWJO software was used to analyze and quantify our FACS data. FACS data was first gated
by excluding debris and then gated for distinct subsets in both erythroblast (Figure 5A) and
HSPC (Figure 5B) sample analyses. For erythroblast panels: Non-Eryths were gated as
CD71¯CD235a¯, EEBs were gated as CD71⁺CD235a¯, and LEBs were gated as
CD71⁺CD235a⁺. For HSPC panels: CMPs were gated as CD34⁺CD38⁺CD45RA+/- CD123+,
GMPs were gated as CD34⁺CD38⁺CD45RA+CD123¯, and MEPs were gated as
18
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CD34⁺CD38⁺CD45RA¯ CD123¯. Geometric mean intensity was used to determine MAFB and
GATA1 expression in CMPs.

235a

A

23

B

CD34CD38

45RA

LIN NEG Cells

Figure 5. Erythroblast and Progenitor Subset Gating. (A) Erythroblast panel: total cells were
excluded for debris on forward and side scatter and then gated for CD71 (x-axis) and CD235a (yaxis) expression to determine Non-Eryth/LEB/EEB populations. (B) Progenitor panel: total cells
were excluded for debris on forward and side scatter and then gated for positive CD34 and CD38
expression followed by subsequent gating of CD45RA (x-axis) and CD123 (y-axis) expression to
determine CMP/GMP/MEP populations.
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MAFB Gene Silencing.
Phase 1 cultured BM controls and MM samples were left in growth factor cocktail for
one day to increase proliferating cells for optimal MAFB silencing using siRNA. On the day of
transfection, medium was aspirated out and cells were resuspended in Opti-MEM. To silence
MAFB a lipid-based transfection medium (X-tremeGENE) was used to allow uptake of the
siRNA into live cells. MAFB siRNA was mixed with transfection reagent and added to cells of
interest one drop at a time. A non-specific FITC labelled scrambled RNA was used as a control
in parallel wells. The FITC scramble will not silence MAFB, but instead will determine
transfection efficiency to help discern on the specificity of MAFB silencing. Four hours after
transfection, cells were replenished with Phase 1 growth cocktail and allowed to culture for
seven days. Transfection efficiency was checked on day 3 through FACS by comparing MAFB
expression of the control (scrambled RNA) to samples that received siRNA. CMPs/GMPs/MEPs
were analyzed by FACS on day 7 after Phase 1 culture was complete. Flow cytometry was
followed as explained previously to determine HSPCs, CMP, GMP and MEP development with
and without MAFB siRNA.
-Control Scramble (FITC Fluorescein Conjugate)-A 10 µM: Santa Cruz Biotechnology, Inc
(Catalog #: sc-36869)
-MAFB siRNA (h) 10 µM: Santa Cruz Biotechnology, Inc (Catalog #: sc-35839)
-Opti-MEM™ I Reduced Serum Medium: Thermo Fisher Scientific Inc (Catalog #: 31985062)
-X-tremeGENE™ siRNA Transfection Reagent: Millipore Sigma (Catalog #: 4476093001)
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Giemsa Staining.
Cytospin fixed and permeabilized cells in IMDM at 100 rpm for 5 minutes. After
cytospin, dipped slides in methanol for 1 minute. Once 1 minute of methanol dip has passed,
dipped slides in May-Grunwald stain for 10 minutes. After 10 minutes, slides are dipped in Tris
(25mM pH 7.4) for 2 minutes and subsequently dipped slides in Giemsa stain for 10 minutes.
Lastly, the slides were rinsed with Milli-Q water and let dry vertically in a slide holder for 30
minutes before viewing under scope.
-Giemsa Stain: Sigma Aldrich, diluted 1ml in 38ml of Milli-Q water (Catalog #: G5637)
-Tris (25mM): Sigma Aldrich, 3.03g Trizma hydrochloride in 1L Milli-Q water adjusted to
7.4pH (Catalog #: 648311)
-May-Grunwald Stain: Sigma Aldrich (Catalog #: MG500)
-IMDM (+L-Glutamine, +25mM HEPES, −Phenol Red, +1% Pen/Strap, +10% FBS, +1%
Plasmocin, +1% Amphotericin): Gibco by Life Technologies (Catalog #: 31980097)

21

22

CHAPTER THREE
RESULTS
MM Patient Samples Have a Lower Number of Total Erythroblasts Versus BM Control
Samples Indicating Diminished Erythropoiesis
Erythropoiesis is split between three phases: the commitment phase, the proliferation
phase, and the maturation phase [53]. During the commitment phase HSCs commit towards
MEPs, and then progress towards the proliferation phase where they develop into EEBs [53].
Lastly, during the maturation phase EEBs mature into LEBs and eventually erythrocytes [53].
Due to our aspirates containing isolated MNCs only, we cannot measure erythrocyte numbers.
However, we measured the erythroblast population and in doing so grasp how erythropoiesis is
occurring in these samples. Samples were analyzed for their erythroblast populations
immediately after thawing from frozen aspirates and designated as day 0 samples. Day 0 analysis
of the erythroblast population compared MM samples with control BM (Figure 6). When
comparing the two: a contour plot of MM sample had a lower number of erythroid cells versus
control BM (Figure 6A). The contour plot has CD71 on the x-axis and CD235a on y-axis to
determine erythroblast population (Figure 6A). Upon further analysis, eleven MM samples and
three control BM samples were quantified per one million BM MNCs for their total erythroblast
populations (Figure 6B). The MM samples displayed a significantly lower total erythroblast
population when compared to the control BM samples. When looking at the different subsets of
our erythroblast population we can examine the EEBs and LEBs. Quantification per one million
BM MNCs of both EEBs and LEBs shows that LEBs are lower in a MM sample compared to a
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control BM sample (Figure 6C). From our day 0 analysis of the erythroblast population, we can
confirm that there is diminished erythropoiesis in our MM samples. The source of the
erythroblast population is the MEPs, which bring into question what their status is.

Figure 6. Increased Non-Erythroid Population and Reduced Erythroblast Population in
MM Compared to Control BM (Day 0). Samples were stained for FACS the same day that
they were processed. (A) Right contour plot (CD71/CD235a) of a control BM sample shows an
erythroid population of 45% and left contour plot (CD71/CD235a) of a MM sample shows an
erythroid population of 15%. (B) Quantification per one million BM MNCs examining the total
erythroblast population of three BM control samples (n=3) and eleven MM samples (n=11) show
a significantly reduced amount of total erythroblast in MM samples compared to BM controls.
Unpaired t test with Welch’s correction assigned a two-tailed P value between control BM and
MM samples for total erythroblasts: <0.001. (C) EEBs (Early EB) and LEBs (Late EB)
encompass the erythroblast population. When looking at these subsets per one million BM
MNCs, we find that LEBs are significantly reduced in MM samples compared to BM controls.
Unpaired t test with Welch’s correction assigned a two-tailed P value between control BM and
MM samples for EEBs: ns and LEBs: 0.001.
MM Patient Samples Have Greater Number of GMPs and Lower Number of MEPs Versus
BM Control Samples (Day 0)
MM and control BM samples were analyzed for CMPs. GMPs, and MEPs immediately
after thawing from frozen aspirates. Samples were designated as day 0 samples and LIN-NEG
population was isolated, and surface stained with conjugated antibodies for CMPs, GMPs, and
MEPs. Contour plots for myeloid and erythroid progenitors (Linneg CD34+CD38+ CD123+/CD45RA+/-) of a control BM sample compared against a MM sample demonstrates that the
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percentage of GMPs increases from 13% in control BM to 52% in MM sample (Figure 7A).
MEPs alternatively, decreased from 64% in a control BM sample to 19% in a MM sample
(Figure 7A). When examining with more samples and quantifying per one million HSPCs we
find a similar trend of MM samples containing a higher number of GMPs and lower number of
MEPs when compared to control BM samples (Figure 7B).

Figure 7. GMPs Increase and MEPs Decrease in MM Samples Compared to Control BM
(Day 0). (A) Day 0 CD34+CD38+ cells from lineage negative cells were gated for CD45RA on
X-axis and CD123 on Y-axis in contour plots from FACS. MM sample had 52.4% of GMPs /
19.6% of MEPs / and 20.2% of CMPs in HSPC subset compared to 13.2% GMPs / 64.0% MEPs
/ and 10.5% CMPs in BMC. (B) Distribution of bone marrow progenitors represented in bar
graphs. Three Day 0 BM Control samples (n=3) were used for control metric and five Day 0 MM
samples including three MM samples that were average amongst several trials (n=5) were used
for MM sample aggregate. Unpaired t test with Welch’s correction assigned a two-tailed P value
between control BM and MM samples for CMPs: ns, GMPs: 0.01, and MEPs: 0.005.
MM Patient Samples Have Increased MAFB Expression and Decreased GATA1
Expression Versus BM Control Samples (Day 0)
After surface staining Day 0 samples of BM controls and MM samples were incubated
with anti-MAFB and anti-GATA1 after permeabilizing and fixing the cells. Geometric mean
intensities of FITC-conjugated MAFB antibody and PE conjugated GATA1 antibody was
measured in CMPs of the MM samples and compared to the BM control samples (Figure 8).
CMPs were used for measurements due to the influences MAFB and GATA1 have in
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determining whether CMPs differentiate into GMPs (high MAFB/low GATA1) or MEPs (high
GATA1/low MAFB). Contour plots (CD34+CD38+) overlayed control BM samples with MM
samples to show expression patterns. Produced overlay of MAFB plot (MAFB on x-axis)
signifies MM samples having most of its CMPs towards the right of the plot indicating positive
expression, while control BM samples have most of its CMPs toward the left indicating negative
expression (Figure 8A). When comparing absolute geometric mean intensities of MAFB: MM
samples gave us a mean expression of 2,500 versus 1024 for our control BM samples (Figure
8A). Alternatively, produced overlay of GATA1 plot (GATA1 on x-axis) signifies MM samples
having most of its CMPs towards the left of the plot indicating negative expression, while control
BM samples have most of its CMPs toward the right indicating positive expression (Figure 8B).
When comparing absolute geometric mean intensities of MAFB: MM samples gave us a mean
expression of 7,650 versus 12,570 for our control BM samples (Figure 8B). When normalizing
our MAFB and GATA geometric mean intensities towards our control BM we find that MAFB
is increased and GATA1 is decreased in MM samples compared to control BM samples (Figure
8C). There is a fine balance and tuning between the transcription factors MAFB and GATA1.
Thus, the most apt way to view the changes in MAFB and GATA1 between different conditions
is as a ratio. The ratio of MAFB:GATA1 for the BM control samples was 12:1 while the MM
samples was 1:3. This clearly denotes that the MAFB:GATA1 ratio increases in MM samples
compared to BM control samples.
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Figure 8. MAFB Expression is Higher and GATA1 Expression is Lower in CMPs of MM
Samples Versus BM Control Samples (Day 0). (A) Day 0 representative overlay of
intracellular expression of MAFB in CMPS from MM (red) and Control BM (Black). Linneg
CD34+CD38+ CD123+ CD45RA- (CMPs) from six MM samples (n=6) and three BM control
samples (n=3). Numbers indicate absolute geometric mean expression followed by standard error
of measurement (SEM). There is more positive expression of MAFB in CMPs of MM samples as
opposed to BM control samples. (B) Day 0 representative overlay of intracellular expression of
GATA 1 in CMPS from MM (red) and Control BM (Black). Linneg CD34+CD38+ CD123+
CD45RA- (CMPs) from three MM samples (n=3) and three BM control samples (n=3). Numbers
indicate absolute geometric mean expression followed by standard error of measurement (SEM).
Most of the GATA1 expression is negative in MM samples indicating lower expression of
GATA1 in MM samples compared to BM controls. (C) Bar graphs of the geometric mean
fluorescent intensity of MAFB and GATA 1 normalized to Control BM as 100 (arbitrary set).
MAFB = 174; GATA1 = 54 in MM versus 100 in Control BM. Statistical analysis was done
using Wilcoxon Signed Rank Test to assign a two-tailed P value between normalized MAFB
MM samples (0.0012) and between normalized GATA1 MM samples (0.2500).
After Phase 1 Expansion MM Patient Samples Have Greater Number of GMPs and Lower
Number of MEPs versus BM Control Samples (DAY 6)
Conclusions drawn from Day 0 samples can only tell us details at a certain time-point. In
order to confirm a myeloid bias is the reason for increase in GMPs and decrease in MEPs as seen
in day 0 analysis we must determine the commitment pattern of the HSCs in MM samples. In
addition, the environment/situation vary amongst patient samples and controls. For these reasons
we place our samples in phase 1 culture. The phase 1 culture maintains HSPCs in same culture
conditions ex-vivo and allows us to delineate the HSPCs commitment profile in MM. These
samples were denoted as day 6. Day 6 analysis showed similar profiles to day 0 analysis of
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CMPs, GMPs, and MEPs for MM samples. Contour plots for myeloid and erythroid progenitors
(Linneg CD34+CD38+ CD123+/- CD45RA+/-) of a control BM sample compared against a MM
sample demonstrates that the percentage of GMPs increases from 11% in control BM to 59% in
MM sample (Figure 9A). MEPs alternatively, decreased from 65% in a control BM sample to
20% in a MM sample (Figure 9A). When examining with more samples and quantifying per one
million HSPCs we find that while CMPs had no significant difference, GMPs were significantly
increased, and MEPs were significantly decreased in MM samples compared to control BM
samples (Figure 9B).

Figure 9. GMPs are Increased and MEPs are Reduced in MM Samples Versus BM Control
Samples Placed in Phase 1 Expansion (Day 6). (A) Day 6 CD34+CD38+ cells from lineage
negative cells were gated for CD45RA on X-axis and CD123 on Y-axis in contour plots from
FACS. MM sample had 58.5% of GMPs / 20.3% of MEPs / and 6.04% of CMPs in HSPC subset
compared to 11.3% GMPs / 64.7% MEPs / and 11.0% CMPs in BMC. (B) Distribution of bone
marrow progenitors represented in bar graphs. Two Day 6 BM Control samples (n=2) were used
for control metric and three Day 6 MM that were average amongst several trials (n=3) were used
for MM sample aggregate. Unpaired t test with Welch’s correction assigned a two-tailed P value
between control BM and MM samples for CMPs: ns, GMPs: 0.02, and MEPs: 0.01.
MAFB Expression is Higher and GATA1 Expression is Lower in MM samples After Phase
1 Expansion (Day 6)
As with day 0, day 6 samples were similarly incubated with anti-MAFB and antiGATA1. Geometric mean intensity of MAFB and GATA1 was measured in CMPs of day 6
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samples (Figure 10). Contour plots (CD34+CD38+) overlayed control BM samples with MM
samples to show expression patterns. Produced overlay of MAFB plot (MAFB on x-axis)
signifies MM samples having most of its CMPs towards the right of the plot indicating positive
expression, while control BM samples have most of its CMPs toward the left indicating negative
expression (Figure 10A). When comparing absolute geometric mean intensities of MAFB: MM
samples gave us a mean expression of 2,522 versus 1485 for our control BM samples (Figure
10A). Inversely, produced overlay of GATA1 plot (GATA1 on x-axis) signifies MM samples
having most of its CMPs towards the left of the plot indicating negative expression, while control
BM samples have most of its CMPs toward the right indicating positive expression (Figure 10B).
When comparing absolute geometric mean intensities of MAFB: MM samples gave us a mean
expression of 7,899 versus 24,094 for our control BM samples (Figure 10B). When normalizing
our MAFB and GATA geometric mean intensities towards our control BM we find that MAFB
is increased and GATA1 is decreased in MM samples compared to control BM samples (Figure
10C). Looking again at MAFB and GATA1 expression as a ratio we find the ratio of
MAFB:GATA1 for the BM control samples is 16:1 while the MM samples is 1:3. This conveys
that there is a increase in the ratio of MAFB:GATA1 expression in MM samples compared to
BM control samples.
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Figure 10. Phase 1 Expanded CMPs Display Higher MAFB Expression and Lower GATA1
Expression in MM samples Versus BM Control Samples (Day 6). (A) Day 6 representative
overlay of intracellular expression of MAFB in CMPS from MM (red) and Control BM (Black).
Linneg CD34+CD38+ CD123+ CD45RA- (CMPs) from four MM samples (n=4) and two BM
control samples (n=2). Numbers indicate absolute geometric mean expression followed by
standard error of measurement (SEM). There is more positive expression of MAFB in CMPs of
MM samples as opposed to BM control samples. (B) Day 6 representative overlay of
intracellular expression of GATA 1 in CMPS from MM (red) and Control BM (Black). Linneg
CD34+CD38+ CD123+ CD45RA- (CMPs) from four MM samples (n=4) and two BM control
samples (n=2). Numbers indicate absolute geometric mean expression followed by standard error
of measurement (SEM). Most of the GATA1 expression is negative in MM samples indicating
lower expression of GATA1 in MM samples compared to BM controls. (C) Graphical
quantification of the four MM samples and two BM control samples for MAFB and GATA1.
BM control samples were set at an arbitrary geometric mean expression of 100 and MM samples
were normalized against that giving an averaged expression of 190.9 for MAFB and averaged
expression of 28.5 for GATA1. Statistical analysis was done using Wilcoxon Signed Rank Test
to assign a two-tailed P value between normalized MAFB MM samples (0.1250) and between
normalized GATA1 MM samples (0.1250).
Myeloma Cells Do Not Seem to Influence Myeloid Bias
To determine whether myeloma cells contribute to myeloid bias of HSPCs, we isolated
the myeloma cells from MM samples and reseeded them into control BM. Both MM samples
without myeloma cells present and reseeded control BM were placed in phase 1 culture to
identify commitment potential (i.e. myeloid bias). Day 0 MM sample and control BM sample
was analyzed to determine effective surface markers for myeloma cell extraction. Literature
denotes that CD138 and CD38 are used as markers for malignant plasma cells [54]. Contour plot
with gating on CD138 (x-axis) and CD38 (y-axis) defining our myeloma population demonstrate
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that 28% of MM samples fall within this context while less than 1% of control BM have cells
that are CD138+CD38+ (Figure 11A). In addition, control BM was mostly negative for CD138
with most of the cell population lying to the left of the contour plot (Figure 11A). CD138⁺
CD38¯ are still myeloma cells [55]. With justification of CD138+ cells being present in mostly
MM samples, it was used to pull entire myeloma population. When myeloma (CD138+) cells
were reseeded into BM controls and carried through phase 1 culture we found that there was no
significant difference in CMPs, GMPs, and MEPs between it and intact BM controls (Figure
11B). Myeloid and erythroid progenitors were quantified per one million HSPCs. MM samples
that had their myeloma (CD138+) cells extracted were similarly placed in phase 1 culture and
denoted as MM CD138¯ samples. When quantifying per one million HSPCs, myeloid bias
persisted in MM samples without the presence of myeloma (CD138+) cells as compared to BM
controls (Figure 11C). This resulted in an increase in GMPs and decrease in MEPs in MM
CD138¯ samples compared to BM control samples (Figure 11C).
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Figure 11. Myeloma Cells Do Not Seem to Influence Myeloid Bias. (A) Contour plot of day 0
MM sample and day 0 control BM sample gated for CD138 and CD38. Myeloma sample (red)
has cells that are positive for both CD38 and CD138 and this accounts for around 28%. Control
BM sample (black) has cells that are mostly negative for both CD38 and CD138 and this
accounts for less than 1%. (B) CMP/GMP/MEP BM control vs. BM control with CD138+
cells. Before phase 1 culture CD138 positive cells were reseeded into two (n=2) BM Controls
(BMC) and compared with two (n=2) BMCs that did not get reseeded. No significant difference
was observed in CMPs, GMPs, and MEPs between BMC with CD138 positive cells and BMC
without CD138 positive cells. Unpaired t test with Welch’s correction assigned a two-tailed P
value between control BM and control BM with CD138+ cells for CMPs: ns, GMPs: ns, and
MEPs: ns. (C) BM control vs. MM samples with CD138- cells. CD138 positive cells were
isolated from five MM samples and compared to three BMCs. CMPs when comparing the two
types of samples did not have a significant difference. GMPs and MEPs did display a significant
difference between the two types of samples indicating that myeloid bias is maintained in MM
samples without the presence of CD138 positive cells. Unpaired t test with Welch’s correction
assigned a two-tailed P value between control BM and MM samples with CD138- cells for
CMPs: ns, GMPs: 0.01, and MEPs: 0.005.
HSPCs Express All Alpha-and-Beta-Adrenergic Receptor Sub-Types
HSPC subset from Linneg population was used to determine presence of Alpha- and Betaadrenergic receptor sub-types. Histogram overlay of HSPCs from control BM sample confirms
positive expression of all Alpha- and Beta-adrenergic receptor sub-types (Figure 12A). Positive
expression was determined based off secondary antibody control which acts as a negative
control. All receptor subtypes where on the right of secondary controls on the histogram plot,
denoting positive expression. Geometric mean intensity was measured in all adrenergic receptor
sub-types in HSPCs from a MM sample and control BM samples (Figure 12B). Alpha2-andBeta1-adrenergic receptors have mean intensities between 5000 and 10,000 while Alpha1-Beta2Beta3-adrenergic receptors mean intensities above 10,000 (Figure 12B). Comparing adrenergic
receptor expression of HSPCs from control BM samples to the MM sample, we find that
expression patterns are similar between the two (Figure 12C).
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Geometric Mean Intensity (FITC)

Figure 12. All Alpha-and-Beta-Adrenergic Receptor Sub-Types are Present on HSPCs.
Phase 1 HSPCs incubated with primary AR antibodies and then attached with secondary FITC
conjugated antibodies. (A) Histogram overlay of HSPCs from control BM show positive
expression for all AR sub-types. (B) Geometric Mean Receptor Expression. Bar graph of
geometric mean intensity of different Alpha-and-Beta-AR subtypes of HSPCs cumulatively from
control BM samples and MM sample. Alpha1-AR (n=3), Alpha2-AR (n=2), Beta1-AR (n=3),
Beta2-AR (n=2), Beta3-AR (n=3). (C) Chart conveying AR expression of HSPCs between
control BM sample and MM sample. Similar expression patterns of AR subtypes exist between
control BM and MM sample (comparing Mean fluorescent intensity-MFI).
Alpha-Adrenergic Receptor Stimulation Does Not Cause Myeloid Bias; Beta-Adrenergic
Receptor Stimulation Does
Control BM samples placed in phase 1 cultures were treated with phenylephrine (PE) and
isoproterenol (ISO) at concentrations of 1pM, 1nM, and 1μM. PE is an Alpha-adrenergic
receptor agonist and ISO is a Beta-adrenergic receptor agonist [56,57]. CMPs, GMPs, and MEPs
were examined per one million HSPCs to determine effect of Alpha- and Beta-adrenergic
receptor stimulation on myeloid bias (increased GMPs/decreased MEPs). In terms of Betaadrenergic receptor stimulation: increasing concentrations of ISO directly correlated to GMP
levels and inversely correlated to MEP levels (Figure 13A). As ISO concentration increased,
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GMPs increased and MEPs decreased (Figure 13A). On the other hand, in terms of Alphaadrenergic receptor stimulation: increasing concentrations of PE did not seem to influence GMP
or MEP levels (Figure 13B). PE dosage response kept GMPs and MEPs relatively unchanged
from no PE being dispensed to PE being dispensed at highest concentration of 1μM (Figure
13B). Beta-adrenergic receptor stimulation resulted in CMPs having a myeloid bias, but Alphaadrenergic receptor stimulation did not affect CMP differentiation. To confirm the effects of
Beta-adrenergic receptor stimulation on myeloid bias, propranolol was used. Propranolol is a
non-specific Beta-adrenergic receptor antagonist that binds to the receptor and blocks/prevents it
from being stimulated [58]. Various dosages of propranolol were administered to control BM
samples placed in phase 1 culture and then subsequent dosages of ISO were added after.
Propranolol was administered at two orders higher than ISO concentration, except for at 1μM
where it was administered at equal parts (1μM). This was compared to control BM samples
receiving no propranolol. Propranolol treatment led to slight decreases in GMPs and recovery of
MEPs during all conditions (Figure 13C). At the picomolar and micromolar condition, GMPs
were significantly reduced, and at picomolar and nanomolar MEPs were significantly elevated
(Figure 13C). Beta-adrenergic receptor stimulation is influential to myeloid bias as both blocking
and stimulating the receptor has an impact on the bias. Stimulating the receptor leads to the bias
and blocking the receptor negates the bias.
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ISO 1pM: PROP 100pM
ISO 1nM: PROP 100nM
ISO 1μM: PROP 1μM

Figure 13. Alpha-Adrenergic Receptor Agonist (Phenylephrine) Does Not Alter
GMPs/MEPs; Beta-Adrenergic Receptor Agonist (Isoproterenol) and Antagonist
(Propranolol) Do Alter GMPs/MEPs. (A) CMP/GMP/MEP Isoproterenol Dosage Response.
4 trials (n=4) where conducted using 1pM, 1nM, and 1μM of isoproterenol (ISO) added to
control BM samples in phase 1 cultures. ISO has little effect on CMPs and seems to increase
GMPs and decrease MEPs with increasing concentrations. (B) CMP/GMP/MEP
Phenylephrine Dosage Response. 2 trials (n=2) where conducted using 1pM, 1nM, and 1μM of
phenylephrine (PE) added to control BM samples in phase 1 cultures. PE has little effect on
CMPs, GMPs and MEPs with increasing concentrations. (C) GMP/MEP Propranolol Study. 4
trials (n=4) were conducted on control BM samples placed in phase 1 cultures. 100pM, 100nM,
and 1μM of propranolol (PROP) was administered to cells in separate wells. One hour later cells
were stimulated with 1pM, 1nM, and 1μM of ISO in corresponding wells matching PROP
concentrations. This was compared to cells being stimulated with ISO alone. The addition of
propranolol effectively blocked ISO stimulation and led to a decrease in GMPs and increase in
MEPs in all conditions.
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Alpha Adrenergic Receptor Stimulation Does Not Alter MAFB/GATA1 Expression; Beta
Adrenergic Receptor Stimulation Elevates MAFB Expression and Reduces GATA1
Expression
Control BM samples were placed in phase 1 culture and tested with four different
conditions to confirm effects of adrenergic stimulation on MAFB and GATA1 expression. The
first condition involved no stimulation or blockage of adrenergic receptors. The second condition
involved stimulation with 1μM of Alpha-adrenergic receptor agonist phenylephrine. The third
condition involved stimulation with 1μM of Beta-adrenergic receptor agonist isoproterenol. The
last condition involved blockage of Beta-adrenergic receptors using the antagonist, propranolol
at 1μM followed by stimulation with isoproterenol at 1μM. All conditions were incubated with
anti-MAFB and anti-GATA1 after completion of phase 1 to determine MAFB/GATA1
expressions based on adrenergic receptor activity. Geometric mean intensities were measured for
MAFB and GATA1 in CMPs and normalized to no stimulation condition which was arbitrarily
defined as 100. Phenylephrine condition did not change much from the no stimulation condition
giving values of 101 for MAFB and 99 for GATA1 (Table 2). Isoproterenol condition did change
from no stimulation condition by increasing MAFB by 25% and decreasing GATA1 by 50%
(Table 2). Lastly, the propranolol condition reduced MAFB expression by 32% and elevated
GATA1 expression by 44% compared to isoproterenol condition (Table 2). When looking at
MAFB:GATA1 ratio in the isoproterenol condition it is 1:2.5. Effective blockage of
isoproterenol stimulation using propranolol results in MAFB:GATA1 ratio improving to 1:1.
This is similar to no stimulation being present.
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Table 2. Alpha-Adrenergic Receptor Agonist (Phenylephrine) Does Not Affect
MAFB/GATA1 Expression; Beta-Adrenergic Receptor Agonist (Isoproterenol) and
Antagonist (Propranolol) Does Effect MAFB/GATA1 Expression. MAFB and GATA1
geometric mean intensity/mean fluorescent intensity (MFI) was measured in Linneg CD34+CD38+
CD123+ CD45RA- (CMPs) from control BM in four condition: (1) no stimulation, (2)
phenylephrine-Alpha adrenergic receptor stimulation, (3) isoproterenol-Beta adrenergic receptor
stimulation, and (4) propranolol-Beta adrenergic receptor blockage followed by isoproterenolBeta adrenergic receptor stimulation.

MAFB Silencing in MM Samples and ISO Stimulated Control BM Leads to Recovery of
MEPs and Decline in GMPs
MAFB was silenced in MM samples using a lipid-based siRNA of MAFB along with a
transfection reagent. This was compared to MM samples were MAFB was not silenced to
determine if MAFB was the cause of myeloid bias (increase in GMPS/decrease in MEPs) seen in
MM samples. Transfection efficiency was determined to be around 37% (Figure 14). This was
measured through comparing the MAFB expressing subset of a MM sample with and without
siRNA after 3 days of phase 1 culture (Figure 14). The MAFB siRNA used was also validated
from previous studies done by the lab [44]. Contour plots of myeloid and erythroid progenitors
(Linneg CD34+CD38+ CD123+/- CD45RA+/-) of MAFB silenced MM sample versus not silenced
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MM sample covey GMP percentages out of HSPC population decreasing from 46% in not
silenced to 15% in silenced. Inversely, MEP percentages out of HSPC population increased from
30% in not silenced sample to 47% in silenced sample (Figure 15A). Including more MM
samples, myeloid and erythroid progenitors quantified out of one million HSPCs, showed a
similar trend (Figure 15B). GMPs were reduced and MEPs were elevated when MAFB was
silenced in MM samples (Figure 15B). To see the effects of MAFB silencing on Beta-adrenergic
receptor stimulation, a control BM sample was silenced and then stimulated with isoproterenol.
This was quantified out of one million HSPCs and compared to a control BM sample receiving
no stimulation and to a control BM sample receiving stimulation but no MAFB silencing (Figure
15C). Silencing MAFB in isoproterenol stimulated control BM led to a decrease in GMPs and an
increase in MEPs compared to when MAFB was not silenced in stimulated control BM (Figure
15C).

Figure 14. Transfection Efficiency and Validation of MAFB siRNA. 3 days after MM sample
was transfected with MAFB siRNA in phase 1 culture, cells were incubated with FITC
conjugated MAFB antibody and then taken to FACS to measure MAFB expression. MAFB
subsets contain cells that are expressing MAFB. Subtracting the MAFB subset of the MM
sample that did not receive the MAFB siRNA (72.5%) from the MM sample that did receive the
MAFB siRNA (35.5%) we find a difference of 37%. This percentages entails the validation and
efficiency of the MAFB siRNA that was used for this experiment. 37% of cells were successfully
transfected using this MAFB siRNA.
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Figure 15. MAFB Silencing Resolves/Mitigates Myeloid Bias in MM Samples and ISO
Stimulated Control BM. (A) After phase 1 completion, CD34+CD38+ cells from lineage
negative cells were gated for CD45RA on X-axis and CD123 on Y-axis in contour plots from
FACS. MM sample had 46% of GMPs / 30% of MEPs / and 20% of CMPs in HSPC subset
compared to 15% GMPs / 47% MEPs / and 32% CMPs in MM sample with silenced MAFB. (B)
CMP/GMP/MEP MM MAFB Silencing Study. Two MAFB silencing trials were comprised of
a total of four non-silenced MM samples (n=4) and four silenced MM samples (n=4). Unpaired t
test with Welch’s correction assigned a two-tailed P value between MM samples with and
without MAFB silencing for CMPs: ns, GMPs: 0.02, and MEPs: 0.01. (C) CMP/GMP/MEP
CBM w ISO MAFB Silencing Study. One MAFB silencing trials was comprised of a nonsilenced CBM sample (n=1), a non-silenced CBM sample stimulated with ISO (n=1) and a
silenced CBM sample stimulated with ISO (n=1).
MM Sample and Phase 1 Beta Stimulated Control BM Commitment Patterns Lead to
Diminished Erythroblast Development and Increased Non-Erythroid Development
During phase 1 culture a control BM sample was stimulated with 1μM of isoproterenol.
Another control BM sample was reseeded with CD138+ cells from MM sample before the start
of phase 1 culture. A control BM sample and MM sample were also placed in phase 1 culture.
All four conditions were then carried for ten extra days into phase 2 culture after completion of
six-day phase 1 culture. Besides phase 2 growth cocktail consisting of SFEM, EPO, HT, and
SCF nothing was added to phase 2 cultures. On day 16 cells from all 4 conditions were collected
for FACS and giemsa stained for image analysis. Giemsa staining for the control BM condition
displays cells that: have colony formation, are not over-crowded, and mostly erythroblasts
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(Figure 16A). Giemsa staining for the MM condition displays that: myeloma cells are present,
colony formation is sparse, and there are very few erythroblasts (Figure 16A). Giemsa staining
for the control BM with CD138+ myeloma cells displays that: myeloma cells are present, colony
formation still present but not as defined as control BM condition, and that erythroblasts are
present at slightly less density than control BM condition (Figure 16A). Lastly, giemsa staining
for the control BM with 1μM of isoproterenol displays that: cells are over-crowded, and that
there are many other cells besides erythroblasts though erythroblasts are still present (Figure
16A). The image analysis is reaffirmed from contour plots using CD71 and CD235a to set
appropriate gates for non-erythroid cells (CD71¯CD235a¯), EEBs (CD71+CD235a¯), and LEBs
(CD71+CD235a+). Non-erythroid cells were the most prevalent in the MM sample and the
control BM with 1μM isoproterenol sample where it accounted for 20% and 30% of all MNCs
from phase 2 culture (Figure 16B). Control BM and control BM reseeded with CD138+
(myeloma) cells were drastically less, as non-erythroid cells accounted for 6% and 4% of all
MNCs from phase 2 culture (Figure 16B). The LEB percentages for the four conditions gave an
opposite trend from the non-erythroid percentages. LEBs were the most prevalent in the control
BM sample and the control BM sample reseeded with CD138+ (myeloma) cells where it
accounted for 50% and 42% of all MNCs from phase 2 culture (Figure 16B). LEBs for MM
sample and the control BM with 1μM isoproterenol sample accounted for 20% and 30% of all
MNCs from phase 2 culture (Figure 16B). EEB percentages had only an 8% difference between
the four conditions ranging from 5% to 13% (Figure 16B).
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Figure 16. Beta Adrenergic Stimulation During Commitment Stage Leads to Increases in
NonE and Diminished Erythroid Development. ISO and CD138+ myeloma cells were added
to separate CBM at the start of phase 1 culture. Along with these two conditions a CBM sample
and MM sample were also placed in phase 1 culture. Once phase 1 culture was completed, cells
were carried into phase 2 culture (SFEM/EPO/SCF/HT). Nothing was added in phase 2 culture.
(A) Giemsa staining of the four conditions. CBM: Colony formation, not over-crowded,
mostly erythroblasts (pink/blue, small, round cells); CBM + ISO: Over-crowded, many other
cells besides erythroblast though erythroblast still present; MM: myeloma (big translucent,
blue/purple) cells present, very few erythroblasts (pink/blue, small, round cells), not much
colony formation; CBM + MM: myeloma (big translucent, blue/purple) cells present, colony
formation still present but not as defined as CBM, erythroblasts (pink/blue, small, round cells)
are present at slightly less density than CBM. (B) Contour plots of all four conditions gating
for CD71+/- and CD235a+/-. Non-erythroblasts (NonE) percentages were based off phase 2
MNC population and gated as CD71¯CD235a¯. NonE for CBM: 6%; MM: 20%; CBM + ISO:
30%; CBM + CD138+(myeloma) cells: 4%. Late-erythroblasts (LEB) percentages were based off
phase 2 MNC population and gated as CD71+CD235a+. LEBs for CBM: 50%; MM: 20%; CBM
+ ISO: 30%; CBM + CD138+(myeloma) cells: 42%. Early-erythroblasts (EEB) percentages were
based off phase 2 MNC population and gated as CD71+CD235a¯. EEBs for CBM: 8%; MM:
5%; CBM + ISO: 5%; CBM + CD138+(myeloma) cells: 13%.
LEBs Are Diminished and Non-Erythroid Cells Are Increased in MM Versus BM Control;
Beta Stimulation Has Little Effect on Erythropoietic Development
A control BM sample and three MM samples were extended into phase 2 culture after
completion of phase 1 culture. After phase 2 completion on day 16, cells were collected and
processed for FACS. Contour plot of a BM control sample and MM sample used CD71+/- and
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CD235a+/- for gating parameters. Based off phase 2 MNCs, the BM control sample had 6% nonerythroid cells (CD71¯CD235a¯), close to 9% EEBs (CD71+CD235a¯), and 51% LEBs
(CD71+CD235a+) (Figure 17A). The MM sample inversely, had 39% non-erythroid cells, close
to 8% EEBs, and 20% LEBs (Figure 17A). To examine the effect of Beta-adrenergic stimulation
on erythropoietic development and not just commitment, isoproterenol was added to MM
samples only during phase 2 culture. This was compared to MM samples that did not receive
isoproterenol stimulation. Quantifications of BM control, MM sample, and MM sample with
isoproterenol stimulation during phase 2 were calculated per one million MNCs. A BM control
sample compared with MM samples demonstrates that there is no significant difference in EEBs
(Figure 17B). LEBs are significantly reduced, and non-erythroid cells are significantly increased
in MM samples compared to a BM control sample (Figure 17B). When comparing MM samples
with and without isoproterenol phase 2 stimulation we find that there is no significant difference
between non-erythroid cells, EEBs, and LEBs (Figure 17B). This indicates that Beta-stimulation
does not contribute to distinctions seen in MM samples and therefore has little effect on
erythropoietic development.
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Figure 17. MM Samples Have Increased NonE and Decreased LEBs Compared to BMC;
ISO Does Not Impact Erythropoietic Development. (A) Contour plots of BMC sample and
MM sample with gating for CD71+/- and CD235a+/-. Non-erythroblasts (NonE) percentages were
based off phase 2 MNC population and gated as CD71¯CD235a¯. NonE for CBM: 6%; MM:
40%. Late-erythroblasts (LEB) percentages were based off phase 2 MNC population and gated
as CD71+CD235a+. LEBs for CBM: 51%; MM: 20%. Early-erythroblasts (EEB) percentages
were based off phase 2 MNC population and gated as CD71+CD235a¯. EEBs for CBM: 9%;
MM: 8%. (B) Quantification per one million BM MNCs examining NonE, EEBs, and LEBs of
one BM control samples (n=1), three MM samples (n=3), and three MM sample with ISO
stimulation during phase 2 (n=3). MM samples with 1μM ISO were stimulated every other day
throughout phase 2 culture. MM samples with and without phase 2 ISO was conducted over two
trials. Unpaired t test with Welch’s correction assigned a two-tailed P value between control BM
and MM samples for EEBs: ns, LEBs: 0.01, and NonE: 0.04. Unpaired t test with Welch’s
correction also assigned a two-tailed P value between MM samples and MM samples + 1μM for
EEBs: ns, LEBs: ns, and NonE: ns.
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CHAPTER FOUR
DISCUSSION
The previous results were gathered while attempting to elucidate the role of the
transcription factors MAFB and GATA1 in causing a myeloid bias in MM due to adrenergic
signaling. The progress gained in this study allowed us to validate the hypothesis that diminished
erythropoiesis in MM is due to the stimulation of adrenergic receptors on HSPCs during early
commitment (Figure 18). This results in the increase of the transcription factor MAFB, which
restricts HSPCs differentiating into MEPs (Figure 18). With reduced MEP production,
subsequent erythrocyte production will also be reduced as a result (Figure 18).

Figure 18. Schematic of the Effects of Beta Adrenergic Signaling on the Myeloid Bias and
Erythroid Development in MM. BM niche HSPCs express Beta-adrenergic receptors in MM
and their stimulation leads to dysregulation of MAFB/GATA1 axis causing a myeloid bias. This
myeloid bias results in decreased erythroid development. Also, contributing to diminished
erythroid development in MM is the myeloma cells.
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In day 0 analysis of the erythroblast population, the presence of a reduced total
erythroblast population was followed by a reduced number of LEBs. Taking into account the low
levels of hemoglobin (below 14 g/dL) along with day 0 analysis, there is an indication of
erythropoietic arrest. It is well documented that erythropoiesis is diminished in MM [4]. There is
evidence based on derived models and protein/nutrient measurements that this occurs at the
developmental stage in MM due to disrupted erythropoietic islands and reduced erythropoietin
and iron levels [59-61]. The formation of erythropoietic islands, and efficient erythropoietin and
iron levels are vital for erythropoietic development [62-65]. Issues in erythropoietic development
are not alone in contributing to diminished erythropoiesis. The commitment stage may also be
compromised. With this in my mind, there was a need to verify if this issue was stemming from
the BM. Thus, we examined the myeloid and erythroid progenitor population at day 0 as well.
The decreased MEP population matched our claims and seemed to arise due to an increased
GMP population. With the source of erythroblasts being MEPs, this indicates a possible cause
for the reduced erythroblast numbers. In accordance, despite varying progressions and degrees of
myeloma present within MM patients, the occurrence of a low number of MEPs resulting from
the increased GMP population was consistent and displays the severity of a possible myeloid
bias in leading to diminished erythropoiesis in MM patients. At this point we can only theorize
whether a commitment issue stemming from a myeloid bias was the cause of the increased
GMPs and decreased MEPs. Further analysis was needed to confirm this claim.
As noted earlier, our lab previously found that the myeloid bias in burn injury was due to
the dysregulation of the MAFB/GATA1 axis [51]. MAFB is elevated while GATA1 is reduced
leading to an increase in GMPs and decrease in MEPs. Having seen this same trend in our day 0
GMPs and MEPs we then analyzed MAFB and GATA1 expression. As expected MAFB was
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elevated and GATA1 was reduced. This Indicates a reason for the increase of GMPs and
decrease of MEPs in MM samples versus BM control as seen from day 0 HSPC analysis. Day 6
HSPC analysis allowed us to confirm whether a myeloid bias was present in our MM samples.
The same trend between day 0 and day 6 of higher GMPs and lower MEPs in MM samples
versus control BM samples indicates that phase 1 expanded early myeloid progenitors’
signatures are maintained during commitment stage. In correlation with a higher number of
GMPs in MM samples, MAFB expression was increased denoting a mechanism for myeloid bias
relationship. The lower MEPs in MM samples compared to BM control, corresponds with
reduced GATA1 expression. This denotes the essential balance between the two transcription
factors for erythroid commitment.
Myeloma cells produce GMCSF which is essential for GMP production [66]. Thus, it can
be reasoned if the myeloid bias that we see in our MM samples is due to the contributions of the
CD138+ myeloma cells and not due to adrenergic receptor stimulation. We were able to conclude
that CD138+ myeloma cells did not cause the myeloid bias seen in the MM samples. This gives
more reason to adrenergic receptor stimulation as being the primary cause for the myeloid bias,
but this needs to be proven. Hence, receptor stimulation studies were conducted. By confirming
the presence of adrenergic receptors on HSPCs from both control BM samples and MM samples,
we can surmise that adrenergic receptor stimulation can occur in these cells. Through Alpha-andBeta adrenergic receptor stimulation using isoproterenol and phenylephrine we found that the
stimulation of Beta receptors resulted in a myeloid bias. We were able to confirm this, using the
non-specific Beta-Blocker: Propranolol. Studies conducted on MAFB and GATA1 demonstrate
that the myeloid bias from isoproterenol stimulation is mediated by the dysregulation of MAFB:
GATA1 ratio. MAFB expression was elevated and in turn GATA1 expression was reduced when
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isoproterenol was added to control BM samples, thus begetting a dysregulation in the MAFB:
GATA1 ratio. Propranolol mitigated the effects from isoproterenol stimulation on MAFB and in
turn GATA1 expression. Inversely, phenylephrine did not affect MAFB or GATA1 expression.
Overall, these experiments convey that the commitment pattern and the transcription profile in
control BM samples with a myeloid bias are predominately orchestrated by Beta-stimulation.
The connection between Beta-adrenergic signaling and MAFB expression in causing a
myeloid bias is correlated through our data up to this point. Silencing MAFB in isoproterenol
stimulated control BM demonstrates that the myeloid bias is dependent on the increase in MAFB
expression. Applying this to our MM samples requires MAFB to also be silenced to determine if
the myeloid bias persists. Silencing MAFB led to the dissipation of the myeloid bias seen in
previous MM samples. This establishes that the increase in MAFB expression is the reason for
the myeloid bias in our MM samples, as it leads to the dysregulation in the MAFB: GATA1
ratio/axis. We derived that MAFB expression increases due to Beta-adrenergic receptor
stimulation. In summation, Beta-adrenergic receptor stimulation results in an increase in MAFB
expression which decreases GATA1 expression (dysregulation MAFB/GATA1 axis), leading to
a myeloid bias in MM.
We have analyzed the impact that Beta-adrenergic signaling has towards erythropoietic
commitment, but we have yet to investigate the given impact on erythropoietic development.
When doing so, we found that while Beta-adrenergic receptor stimulation impedes erythropoiesis
during the commitment stage it does not during the developmental stage. The lingering effects of
the commitment stage though, do influence erythropoiesis at the developmental stage. Increased
non-erythroid cells in MM and isoproterenol stimulated control BM likely stems from the
increased GMPs that resulted from Beta-adrenergic signaling. Additionally, the reduction of
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LEBs likely stems from the decrease in MEPs that came about due to Beta-adrenergic signaling.
This can give a notable reason for the high incidence of anemia in MM patients and a likely
target for treatment.
Further applications of this study can be used to investigate the increased non-erythroid
population in MM and how this may foster the BM cancer environment. The non-erythroid
population may contain a high number of MDSCs. As such, the SNS modulation of
erythropoiesis and myelopoiesis is a concerning issue in MM patients. This is because GMPs are
precursors to MDSCs which help foster myeloma cell survival and proliferation [67]. More
research into this area can greatly benefit MM patients and hopefully improve survival rates.
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